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Simple intermittent heartburn with minor or no esophagitis can be treated with
simple measures including lifestyle changes and antacids as needed, or H2
receptor antagonists (H RA), and has a good outcome. Problematic reflux
includes resistance to therapy, stricture, Barrett's esophagus and aspiration.
Severe reflux esophagitis, often resistant to H2RA therapy, requires more potent
treatment with potent acid suppression using proton pump inhibitors, often
indefinitely. When complicated by stricture, dilatations with potent acid sup-
pression are needed. Barrett's esophagus is subject to esophagitis, which is no
more difficult to treat than other cases ofesophagitis. Reflux in Barrett's esoph-
agus should be treated on its own merits without regard to the presence of
Barrett's epithelium. Dysplasia leading to adenocarcinoma is a different prob-
lem, apparently not influenced by reduced exposure to acid. Indications for
antireflux surgery are quite limited and should be carefully analyzed as a
cost/risk/benefit problem.
INTRODUCTION
As many as 40 percent ofadultAmericans experience heartburn at least once a month
[1]. Although heartburn is the most common symptom ofesophagitis, as many as 70 per-
cent ofall persons with intermittent heartburn have no esophagitis [2] and only 60 percent
of persons with daily heartburn have esophagitis [3]. Perhaps as many as 2 percent of
adults in the U.S. have esophagitis [4], while heartburn and esophagitis are quite uncom-
mon in Japan [5] for unclear reasons.
While the majority ofpatients with heartburn have minimal or no disease, a number
ofpatients withproblematic gastroesophageal reflux (GER)b disease require special atten-
tion. There are several categories ofproblematic GER including patients with esophagitis
or symptoms refractory to treatment [6, 7, 8], those with rapidly recurring esophagitis [1,
9], those with complications such as stricture and Barrett's esophagus and those with air-
way aspiration of refluxate. Treatment for each of these states requires understanding of
the specific causes of abnormal GER, the extent ofthe esophageal disease and the natur-
al history of the disorder. Goals for treatment must be defined so that therapy may be
appropriately applied and the results measured [1, 10, 11].
BASIS FOR TREATMENT STRATEGIES
In general, gastroesophageal reflux is a physiological phenomenon in which gastric
contents intermittently enter the esophagus and are rapidly cleared and neutralized [12].
The highly integrated loweresophageal sphincter (LES)complex accommodates the swal-
lowed bolus, relaxing after swallowing to allow forward passage and preventing reflux at
other times, while allowing gas to escape via belching, i.e., discriminating gas and liquid.
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The inappropriate relaxation of the LES (abnormal transient LES relaxation or TLESR
[12, 13]) is to be distinguished from apermanently incompetent sphincter(LESPless than
10 mm Hg) which allows free reflux by gravity or pressure differential [12, 14]. Sphincter
incompetence (LESP less than 10 mm Hg) in the presence ofacid secretion almost always
leads to esophagitis, but in one study [15] accounted for only 30 percent of cases of
esophagitis. Almost all patients resistant to omeprazole have low LESP [7]. LESP in
infants is generally low, but esophagitis is not common. Excessive frequency or duration
ofTLESRis felt to underlie themajority oftheremaining 70 percent ofcases ofesophagi-
tis [13], presumably coupled with defects in factors protecting the esophageal mucosa
[12]. The LES may also be rendered incompetent by an axial hiatal hernia, which often
additionally functions as an intrathoracic reservoir of gastric contents so that clearance
remains incomplete [12]. Hiatal hernia, however, is present in only 50 percent ofpatients
with esophagitis [6]. Normally, acid gastric contents are rapidly cleared from the esopha-
gus through a combination of reflex responses to acid reflux: propulsive motility is initi-
ated to empty the esophagus and HCO3-secreted by the esophagus and from saliva which
is reflexively stimulated neutralizes remaining acid. It is notclearhow thesereflexes oper-
ate during sleep when salivary flow largely ceases and swallowing is much diminished.
The squamous epithelium of the esophagus is quite impermeable to acid [16, 17].
Maintenance ofmucosal integrity is complex and involves EGF, mucus and HCO3- secre-
tion, blood flow and cellular responses and proliferation in response to injury [12].
Excessive exposure ofthe esophagus to acid and pepsin may result from delayed gas-
tric emptying; in the most extreme case persistent vomiting secondary to pyloric stenosis
or gastroparesis always causes esophagitis though in the ordinary course of events lesser
abnormalities of gastric emptying, which do not cause vomiting, do not probably under-
lie reflux esophagitis [1]. Massive gastric hypersecretion due to gastrinoma (Zollinger-
Ellison syndrome) is frequently associated with esophagitis [19], but in non-ZE hyper-
secretors with BAO (basal acid output) over 15 meq/hr, esophagitis is uncommon [15, 20].
In general, acid and pepsin secretion are not different between patients with either simple
or complicated (stricture, Barrett's) esophagitis and controls matched for age, sex and
coexisting disease such as duodenal ulcer [6, 15, 21]. Nevertheless, stringent reduction in
esophageal acid exposure is the key to successful treatment ofesophagitis [18].
There are no good data defining the conditions necessary to induce and maintain
esophagitis in man [12]. We do not know the necessary duration of exposure, the mini-
mum composition ofthe refluxate, or whether there is any particular time ofday or night
when the esophagus is more susceptible to damage. In experimental animals, acid alone
is much less ulcerogenic even at pH as low as 1.6 [22, 23]. Addition of pepsin to acid at
pH 1.6 rapidly resulted in esophagitis [22]. It would thus appear that pepsin is critical to
the evolution and maintenance of esophagitis and its effective inactivation at pH greater
than 3.5 by adequate acid suppression will allow esophageal healing [14]. Other barrier
breakers may allow acid/pepsin access to the baso-lateral membrane with rapid, serious,
deleterious effect on the mucosa. Such agents include bile salts, aspirin acting systemi-
cally [24], and other drugs like quinaglute, KCl, and tetracycline, among others, acting
locally to cause so-called pill esophagitis, which is localized rather than being typical dis-
tal reflux esophagitis [25].
Disordered motility as in scleroderma [26] or as a consequence of severe esophagitis
[27] prolongs acid/pepsin exposure and compounds the problem.
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THE MEASURED APPROACH TO THERAPY
First steps: The management ofheartburn starts with a goodhistory
The majority of cases of intermittent heartburn respond readily to antacids or single
small doses ofH2 antagonists recently released in non-prescription form [28]. Even asim-
ple increase of salivary flow by the use ofchewing gum may suffice [29]. Such patients
clearly require no diagnostic evaluation or other treatment and most will respond to
change in habits [11], such as reducing the size ofmeals, especially ifthe patient eats only
one large meal per day. For nocturnal heartburn, the patient should allow three to four
hours to elapse between the evening meal, which should be reduced in bulk and fat, and
recumbency to permit gastric emptying and the dissipation of fat effect on the LES.
Avoidance of a bedtime snack and elevation of the head of the bed is often recommend-
ed, though persistence of nocturnal heartburn after change in eating habits might be bet-
ter managed pharmacologically, e.g., with an evening dose of antacid H2RA [35] or pro-
kinetic agents [1]. Other measures recommended include weight reduction, especially if
symptoms are clearly related to recent weight gain, though the role of obesity per se has
notbeen formally distinguished from the concomitant consumption ofhigh-fatfoods [30].
Patients should avoid, if possible, foods or drugs that lower LESP, e.g., fats, chocolate,
coffee, alcohol; anticholinergics, calcium channel blockers, progesterone, aminophylline
or nitrates. Smoking also promotes reflux [31]. The cumulative benefit of dealing with
each of these contributing factors is quite enough to manage reflux in the majority of
patients with symptoms [11] and results may be readily assessed by the presence or
absence of symptoms. Assuming that such patients have minimal or no esophagitis, the
natural history is very favorable. Thus, even if grade I esophagitis is present, 50 percent
will remain unchanged, a further 45 percent will heal spontaneously and only five percent
progress to grade III in three years [32].
When to investigate GER symptomsfurther
The majority of patients with heartburn can be adequately treated with simple mea-
sures without radiographic or endoscopic investigations. Further workup is necessary in
those patients with persistent heartburn, dysphagia, non-cardiac chest pain or airway aspi-
ration. Evaluation starts with a barium contrast radiographic study, preferably with cine-
fluoroscopy recording to confirm and define the extent of reflux including influence of
body position, and the effect ofincreasing intra-abdominal pressure. Such studies should
include the use of sized barium tablets to measure stricture diameter. Endoscopy is
required to assess the degree and extent of damage; biopsy is indicated to diagnose and
classify Barrett's epithelium [33] and to rule out suspected malignancy or infection.
The grading of esophagitis at the outset is important, given the very favorable prog-
nosis of patients with heartburn who have no or only grade I esophagitis [32]. Grade II
esophagitis (linear erosions over less than 10 percent of surface) will heal well with
H2RA, or even cisapride [1], and poses no long-term risk to the patient, seldom progress-
ing to severe grades with complications, especially if NSAIDs are avoided [24] and if
there is no underlying major motor disordersuch as scleroderma. Forthese patients symp-
tom control is probably an adequate benchmark, even though relapse rates are fairly high
[34-37.] Such relapse may require change in treatment.
Grade III and IV esophagitis (severe and/or complicated esophagitis) [1, 9, 34, 38]
represent the hard core ofthe problem. The majority of such cases have severe persistent
heartburn [3, 4, 6, 9, 38, 39] or dysphagia and few, if any, remit spontaneously [1-3, 8-10,
39] and most require long term continuous acid suppressing therapy [7-9]. NSAIDs, espe-
cially aspirin, may contribute significantly to esophagitis and stricture, and overt or sur-
reptitious use ofthese drugs should be diligently investigated [24]. Continuing esophagitis
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may lead to stricture and decrease in motor function, further compounding the problem.
Stricture is moreover a marker for failure to heal [6]. Barrett's esophagus is a separate
problem and at first may be obscured by superimposed esophagitis, and may not be diag-
nosed until the esophagitis is treated. Severe, diffuse esophagitis or discrete esophageal
ulcer pose a risk of bleeding, especially in patients with concomitant NSAID use.
Endoscopic andradiologic examinations will thus determine the immediate course oftreat-
ment and further studies will be indicated by the response to such treatment.
At this point the patient may be treated and further investigation postponed unless
results oftreatment are suboptimal. Further studies include manometry to define contrac-
tion strength and patterns and to measure LES pressure. This study would also uncover
undiagnosed aperistalsis [7] including that due to scleroderma, in which refractory
esophagitis is common [26]. A 24-hour gastric acid measurement for documentation and
quantitation of acid exposure without treatment best defines the relation of symptoms to
acid reflux. In patients who fail to respond to treatment with proton pump inhibitors, 24
hour gastric acid measurement on treatment, e.g., with omeprazole 20 mg twice daily,
should be done [7, 8, 40, 41]. In patients with concomitant duodenal ulcer or marginal
ulcer following gastrectomy, ZES should be excluded by appropriate tests of serum gas-
trin and gastric analysis [19].
PHARMACOLOGIC TREATMENT FOR
PROBLEMATIC REFLUX ESOPHAGITIS
In those cases with problematic esophagitis, grade III or IV, stricture, or Barrett's
esophagus, and airway aspiration, specific long term treatment goals should be defined.
Esophagitis resistant to treatment
In the past, resistance to treatment has in practice been generally defined by failure to
heal with H2RA with six to 12 weeks treatment [6-9, 34-38]. In a meta-analysis "duode-
nal ulcer," doses ofH2RA failed to heal two-thirds ofcases ofesophagitis [42] and many
controlled trials showed no benefit overplacebo [1]. Such resistance was soon found to be
a function ofinitial severity ofesophagitis, e.g., 78 percent ofgrade II healed at six weeks
compared to 30 percent and 23 percent, respectively, for grade III and IV [34] and raniti-
dine 150 mg/day or equivalent did not prevent relapse [7, 34-36, 43].
Even though in such patients underlying acid secretion is not different from those
who healed [6], the key to effective treatment appears to be acid suppression to elevate
gastricjuice pH outside the range ofpeptic proteolytic activity [18, 23], and this may be
most effectively achieved by proton pump inhibitors [7, 14,42,44]. Because ofthe greater
potency ofPPI, so-called resistantesophagitis, i.e., resistant to H2RA [6, 7] is now almost
always treatable with omeprazole or lansoprazole [38, 41-44] at one or two doses per day
[7, 41]; a very few patients require higher doses [7, 8] and resistance to therapy has to be
redefined in the era ofPPI therapy.
Rare cases ofresistance to doses greater than 60 mg omeprazole/day are reported [8,
40]. Such resistance to high doses of proton pump inhibitors should be investigated by
manometry which almost always shows very low LESP [7, 8] by measurement ofgastric
secretion on treatment and 24-gastric gastric acid measurements to document at least one
source of resistance [8]; other causes such as undisclosed use ofNSAIDs [24], underly-
ing ZES [19] or scleroderma [26] should be considered. Acid clearance is decreased in
patients with higher grades ofesophagitis [27] and both motor activity [8] and acid clear-
ance in those with stricture [8, 27]. Such defectsmay explain why stricture is such astrong
markerforresistantesophagitis (22/30resistantpatients had stricture vs. 3/20 who healed)
[6], andwhy there is even initial resistance toomeprazole treatment [9] and slow response,
which requires up to two or more months to heal [7-9, 18, 37]. Most or all such patients
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require indefinite treatment with proton pump inhibitors because the relapse rate is almost
100 percent [9, 18, 45]. Even on 20 mg omeprazole/day as many as 33 percent ofpatients
relapse in 12 months [7, 8, 37, 38] (generally, however, only to grade I). With relapse, such
patients require higher doses for some time [7, 45]. Rarely they should be considered for
surgery [10] (see below). No data are available on the outcome ofsuch patients. There are
no data on the effect of NSAIDs or their discontinuation on the relapse rate in esophagi-
tis, particularly grade III and IV.
ESOPHAGEAL STRICTURE
Reflux esophagitis, usually at least grade III, may be complicated by stricture which
always occurs at the squamo-columnarjunction and extends proximally [46]. In cases of
Barrett's esophagus, strictures form at the neosquamous-columnarjunction [46]. By con-
trast, strictures due to other causes such as caustic or pill-induced stricture may occur at
more proximal locations [25].
The diagnosis of peptic stricture is suggested by progressive dysphagia for solids,
generally preceded by prolonged symptomatic reflux. Dysphagia requires diagnosis by
barium contrast studies, including sizing of the stricture using barium tablets [46, 47].
When the lumen is less than 12 mm, dysphagia is always present and the patient may pre-
sent with impaction. Endoscopy is also necessary to determine the degree ofesophagitis,
the appearance ofthe stricture, to rule outmalignancy and determine whether the Barrett's
epithelium is present. Manometry to characterize motility of the body and the LESP are
important in planning therapy, while 24-hour ambulatory pH measurement will define the
degree of reflux underlying the disorder. Aspirin or other NSAID may contribute to
esophagitis and stricture by promoting fibrogenesis [48]. In our patient population 80 per-
cent of stricture patients were currently using NSAIDs (over 80 percent of which was
aspirin) compared to 60 percent with esophagitis only and 23 percent ofcontrols [24, 49].
Careful history together with interview offamily members and measurement ofsalicylate
in blood should be done in each case. ZES should also be ruled out, especially if there is
concomitant duodenal ulcer.
Peptic strictures are frequently associated with abnormally low LESP, and with dis-
ordered motility and especially with diminished acid clearance, all of which contribute to
the persistence ofthe esophagitis and the relapse ofthe stricture requiring repeated dilata-
tion ifthe cycle ofcontinued reflux with damage is not interrupted [8, 27, 46, 47]. It is not
clear whether the disorders of motility and acid clearance are primary or secondary [27]
and whether they are reversible [46]. A small number have severe transmural fibrosis and
in these the condition is irreversible [50]. In cases ofintrinsic loss ofmotor function, such
as scleroderma (or achalasia after Heller myotomy) esophagitis is common (60 percent)
and of these halfhave strictures [26, 51].
Dilatation ofthe stricture alone without eliminating acid/pepsin reflux is seldom suc-
cessful. Before potent acid suppressing therapy was available such patients required mul-
tiple repeated dilatations [46]. H2 antagonists are only slightly better than no therapy [45,
52]. However, with the use of long-term omeprazole, dilatation of the stricture and heal-
ing of the esophagitis is both feasible and cost-effective [49, 53], virtually eliminating
recurrent strictures with omeprazole doses of20 or40mg/day [45, 52]. With this approach
surgery is seldom needed. A case can be made for surgery in young persons who might
otherwise face a lifetime ofexpensive medications [10], and in those with airway aspira-
tion persisting during acid suppression.
Surgical antireflux treatment is aimed at the reflux rather than the stricture and risks,
results and cost of surgery should be compared to those of proton pump inhibitors com-
bined with dilatation [10, 47]. In any event, surgery should not be performed until the
patient has had athorough course oftreatment with dilatations and proton pump inhibitors
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to complete healing of the mucosa and resolution of the stricture. At that point the motor
function of the esophagus should be again studied, as an aperistaltic esophagus is likely
to result in dysphagia and a poor result [50].
There is no good indication for performing simultaneous acid suppressing surgery
(vagotomy or gastrectomy). Moreover, these provide another source of unfavorable out-
come, especially as vagotomy may cause delayedgastric emptying. Iflaparoscopic antire-
flux surgery becomes reliable and good outcome dependable, a better case can be made
for such treatment. This is discussed in the following paperby Perdikis et al. Re-operation
for failed antireflux surgery and resection of strictures carry high morbidity and mortali-
ty [54].
Patients with "pill esophagitis" generally do not require acid suppression therapy
unless there is evidence ofconcomitant reflux disease. Esophageal peptic stricture is a risk
factor for pill impaction; in that case severe stricture may result at the location of the
reflux-induced primary stricture or Schatzki's ring.
BARRETT'S ESOPHAGUS
In S to 12 percent ofpatients with GER undergoing endoscopy the distal esophagus
may be found to be lined with columnarepithelium, so-called Barrett's esophagus (BES).
This condition may also be present in young children [55], raising the possibility ofa con-
genital disorder, since in the fetus the esophagus is lined with columnarepithelium, which
becomes squamous when fetal length exceeds about 230 mm [56]. In adult life Barrett's
esophagus is diagnosedmainly in the age group 40 to 80 [57-59], corresponding to the age
range in which symptomatic esophagitis is usually seen [1, 15]. While it is generally
thought that Barrett's esophagus results from reflux esophagitis [55, 58, 59], the demo-
graphic peculiarities ofthis condition raise questions about the conventional hypothesis of
antecedant acid/pepsin reflux esophagitis with abnormal healing. At least 30 percent of
patients with BES have no history ofheartburn [59]. BES occurs predominantly in whites
(almost 100 percent) and is rare among females who number almost 50 percent of non-
Barrett's esophagitis [15] but who are as equally subject to the other more rationally pre-
sumed sequel ofesophagitis, namely stricture. Thus, in my prior study [15] the proportion
of females with esophagitis who had BES was 6.5 percent compared to 28 percent of
males (p < .01) while the proportions with stricture were 28 percent vs 29 percent, respec-
tively.
There are no pathophysiological factors [12] that explain this gender difference, nor
its rarity in blacks [59]. Moreover, in a study of 30 patients with BES there was no dif-
ference in basal or maximal acid or pepsin secretion between patients with BES and
appropriately matched controls [21]. In examining the possible role of acid and pepsin in
causing BES, there is little convincing evidence of new development or progression of
BES in patients over long termendoscopic observation [57]. Experimentally induced BES
in dogs required both removal of the esophageal epithelium and exposure to histamine-
stimulated gastric secretion to produce BES epithelium [60]. Another problem in ascrib-
ing BES solely to acid/peptic reflux arises from the fact that the extent ofthe BES appears
to be uninfluenced by either reducing acid exposure or failing to do so [57, 58, 61,63].
Antireflux surgery does not result in reduction of extent of BES [55, 61, 63].
Regardless of its pathogenesis, the problems of BES are two-fold; first, in the pres-
ence ofreflux, BES epithelium is subject to damage, and second, and more serious, is the
potential formalignant transformation ofBarrett's epithelium to adenocarcinoma [64-67].
BES is said to be subject to more severe esophagitis [59], perhaps due to the gener-
ally found lower LESP and the frequently defective motility in the body of the esopha-
gus [68, 69]. One study reported 37 percent of BES in scleroderma [25]. In my own
patients the degree ofesophagitis and the prevalence ofdiscrete ulcer and stricture were
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no higher among BES patients than in age, sex and race-matched controls withesophagi-
tis but without BES [21]. Whether or why the columnar epithelium is more susceptible
to damage is notclear since its characteristics as an epithelium, e.g., with respect to resis-
tance to acid, or its ability to secrete mucus and bicarbonate have not been formally
established. Esophagitis in BES does, however, heal readily with conventional PPI treat-
ment for superimposed esophagitis [54] but with the same columnar epithelium.
The principal concern about Barrett's esophagus is the potential for adenocarcinoma
ofthe lower esophagus and cardia [64, 67 70, 71]. Adenocarcinoma in this area is associ-
ated with BES in about 30 percent ofcases, but shares the characteristics ofBES in being
predominantly (6:1) found in white males [67]. Carcinomadeveloping in Barrett's epithe-
lium follows a definable course ofprogressive genomic instability [71] expressed in his-
tological grades ofatypia [70]. It is estimated that about 10 percent ofpatients will devel-
op adenocarcinoma 10 or more years after initial diagnosis [25, 64-66], with relative risk
of about 40 over the age-matched controls [59]. What is not clear is whether inflamma-
tion (esophagitis) or acid exposure in any way influences this process, either in its initia-
tion orprogression. Prevention ofreflux by antireflux surgery does not prevent malignant
evolution [63, 64, 66, 70, 71]. It is too soon to tell whether strict control ofacid secretion
now possible with proton pump inhibitors will by itself influence the long term outcome
[72], but that too seems not to be the case [61, 62].
Acid suppression does not apparently affect atypia or its progression. In the absence
ofesophagitis or symptoms, BES per se requires no therapy except for the difficult ques-
tion of dysplasia. New approaches to reversing Barrett's metaplasia, such as the use of
laser ablation plus acid suppression [62, 73] are encouraging and may change the whole
approach to the problem ofmalignantpotential ofBES, especially the difficulty oftiming
and extent ofsurgery based on thefinding ofdysplasia. The treatmentofreflux in thepres-
ence ofBES should therefore be solely determined by the reflux problems - symptoms,
esophagitis and aspiration - and not by the BES. A decision to recommend antireflux
surgery for proper reflux indications does not alterthe need to continue to survey the BES
[63, 73, 74] and be guided by the endoscopic and histological findings [61, 70, 71].
With better diagnosis [62, 70] and recently available potent acid suppressing drugs
longitudinal studies should help resolve the role of acid and pepsin in the development,
evolution and natural history ofBarrett's esophagus. The metaplasia/dysplasia and cancer
risk thatcomplicate Barrett's may well be a separate problem requiring more than control
of acid/pepsin exposure
SUMMARY
Simple heartburn with minor or no esophagitis can be treated with simple measures
to control symptoms including lifestyle changes and antacids or use ofH2RA as needed.
Problematic reflux esophagitis, resistance to therapy, largely in the more severe degrees of
esophagitis, which is often complicated by stricture, requires more potent treatment but is
almost always manageable by medical means. Proton pump inhibitors at doses sufficient
to raise refluxed gastricjuice pH to more than 3.5 or outside the proteolytic optimum for
pepsin for most ofthe day [14, 42, 44] will heal all cases ofesophagitis, with rare excep-
tions, and prevent relapse with little risk in long term use. Strictures respond to dilatation
and with esophagitis eliminated do not recur. Barrett's esophagus is as subject as squa-
mous epithelium to reflux esophagitis and is similarly responsive to acid suppression ther-
apy, though BES generally remains unchanged, in extent with or without therapy. The
demographics (over 80 percent of BES patients are male and all are white) suggest that
BES may not be a straight-forward result ofreflux esophagitis. The principal problem of
BES is evolution of atypia and malignancy in about 10 percent of BES, and this appears
to be independent of acid reflux or its control.
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The problem of airway aspiration due to reflux is also generally well managed by
adequate acid suppression, though serious episodes of reflux aspiration still may recur
[45] and require antireflux surgery. Surgery for BES with dysplasia requires careful con-
sideration and should not be lightly undertaken except in high grade-dysplasia. New
approaches such as laser ablation should be vigorously pursued.
Indications for antireflux surgery are limited. Even if laparoscopic techniques make
it easier to do, indications should not be relaxed. The best indications are for aspiration
and severe reflux disease where the LESP is incompetent and the patient is young enough
so that the cost, risk and benefit ratios and long term outcome compare favorably with
medical treatment.
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